BusinessAbstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & ExpositionBy Nasdaq OMXMar 14, 2018, 11:45 AM UTC
BusinessZynerba Pharmaceuticals Provides 2018 Clinical and Corporate UpdateBy Nasdaq OMXJan 3, 2018, 9:30 PM UTC
BusinessAgile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial StrategyBy Nasdaq OMXOct 10, 2017, 10:39 PM UTC
BusinessZynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X SyndromeBy Nasdaq OMXSep 28, 2017, 10:30 AM UTC
BusinessAgile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®By Nasdaq OMXJul 27, 2017, 8:12 PM UTC
BusinessCURE Pharmaceutical Expects Increased Demand for Its Enhanced Transdermal Drug Delivery PlatformBy Nasdaq OMXJul 5, 2017, 1:00 PM UTC
BusinessAgile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare ConferenceBy Nasdaq OMXFeb 14, 2017, 9:00 PM UTC
BusinessCannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric FluidBy Nasdaq OMXApr 12, 2016, 11:00 AM UTC
